These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 9387206)

  • 21. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).
    Wiviott SD; Antman EM; Gibson CM; Montalescot G; Riesmeyer J; Weerakkody G; Winters KJ; Warmke JW; McCabe CH; Braunwald E;
    Am Heart J; 2006 Oct; 152(4):627-35. PubMed ID: 16996826
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aspirin-responsive painful red, blue, black toe, or finger syndrome in polycythemia vera associated with thrombocythemia.
    Michiels JJ; Berneman Z; Schroyens W; van Urk H
    Ann Hematol; 2003 Mar; 82(3):153-9. PubMed ID: 12634947
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease.
    Mehta SR; Yusuf S;
    Eur Heart J; 2000 Dec; 21(24):2033-41. PubMed ID: 11102254
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease.
    Topol EJ; Easton D; Harrington RA; Amarenco P; Califf RM; Graffagnino C; Davis S; Diener HC; Ferguson J; Fitzgerald D; Granett J; Shuaib A; Koudstaal PJ; Theroux P; Van de Werf F; Sigmon K; Pieper K; Vallee M; Willerson JT;
    Circulation; 2003 Jul; 108(4):399-406. PubMed ID: 12874182
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
    De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
    Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outpatient treatment of severe peripheral ischemia with intravenous intermittent low-dose iloprost. An open pilot study.
    Banyai S; Jenelten R; Wagner S; Allmann J; Banyai M; Koppensteiner R
    Int Angiol; 2002 Mar; 21(1):36-43. PubMed ID: 11941272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera.
    Gangat N; Wolanskyj AP; Schwager SM; Hanson CA; Tefferi A
    Cancer; 2009 Dec; 115(24):5740-5. PubMed ID: 19806641
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
    Bhatt DL; Topol EJ;
    Am Heart J; 2004 Aug; 148(2):263-8. PubMed ID: 15308995
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanisms of bleeding and thrombosis in myeloproliferative disorders.
    Landolfi R; Marchioli R; Patrono C
    Thromb Haemost; 1997 Jul; 78(1):617-21. PubMed ID: 9198226
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic myeloproliferative disorders.
    Spivak JL; Barosi G; Tognoni G; Barbui T; Finazzi G; Marchioli R; Marchetti M
    Hematology Am Soc Hematol Educ Program; 2003; ():200-24. PubMed ID: 14633783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of pipobroman in the treatment of polycythemia vera: long-term results in 163 patients.
    Passamonti F; Brusamolino E; Lazzarino M; Baraté C; Klersy C; Orlandi E; Canevari A; Castelli G; Merante S; Bernasconi C
    Haematologica; 2000 Oct; 85(10):1011-8. PubMed ID: 11025590
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
    James S; Akerblom A; Cannon CP; Emanuelsson H; Husted S; Katus H; Skene A; Steg PG; Storey RF; Harrington R; Becker R; Wallentin L
    Am Heart J; 2009 Apr; 157(4):599-605. PubMed ID: 19332184
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The efficacy of aspirin in patients with atrial fibrillation. Analysis of pooled data from 3 randomized trials. The Atrial Fibrillation Investigators.
    Arch Intern Med; 1997 Jun; 157(11):1237-40. PubMed ID: 9183235
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-dose aspirin in polycythemia vera.
    Denes AE
    N Engl J Med; 2004 Apr; 350(16):1683-5; author reply 1683-5. PubMed ID: 15088323
    [No Abstract]   [Full Text] [Related]  

  • 35. [Clinical evaluation of the control of antiplatelet therapy through platelet aggregation rate on polycythemia vera associated with thrombocytosis and erythromelalgia].
    Kurihara A; Kobayashi I; Tamura K
    Rinsho Ketsueki; 1989 Jan; 30(1):99-104. PubMed ID: 2716205
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
    Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
    Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols.
    Berk PD; Goldberg JD; Donovan PB; Fruchtman SM; Berlin NI; Wasserman LR
    Semin Hematol; 1986 Apr; 23(2):132-43. PubMed ID: 3704665
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-platelet effects of 100 mg alternate day oral aspirin: a randomized, double-blind, placebo-controlled trial of regular and enteric coated formulations in men and women.
    Ridker PM; Hennekens CH; Tofler GH; Lipinska I; Buring JE
    J Cardiovasc Risk; 1996 Apr; 3(2):209-12. PubMed ID: 8836865
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Polycythemia vera and essential thrombocythemia in young patients.
    Frezzato M; Ruggeri M; Castaman G; Rodeghiero F
    Haematologica; 1993; 78(6 Suppl 2):11-7. PubMed ID: 8039752
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Daily aspirin--only half the answer.
    Spivak J
    N Engl J Med; 2004 Jan; 350(2):99-101. PubMed ID: 14711906
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.